VanEck Associates
TEVA icon

VanEck Associates’s Teva Pharmaceuticals TEVA Stock Holding History

VanEck Associates’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45.9M Sell
1,356,009
-308,449
-19% -$10.3M 0.03% 299
2026
Q1 		$50.1M Buy
1,664,458
+150,394
+10% +$4.84M 0.04% 269
2025
Q4 		$47.3M Buy
1,514,064
+576,158
+61% +$14.2M 0.04% 254
2025
Q3 		$18.9M Sell
937,906
-107,699
-10% -$1.89M 0.02% 373
2025
Q2 		$17.5M Sell
1,045,605
-1,275,287
-55% -$20.6M 0.02% 352
2025
Q1 		$35.7M Buy
2,320,892
+705,197
+44% +$12.6M 0.05% 233
2024
Q4 		$35.6M Sell
1,615,695
-259,692
-14% -$4.72M 0.05% 224
2024
Q3 		$34.5M Buy
1,875,387
+208,673
+13% +$3.65M 0.04% 223
2024
Q2 		$27.1M Buy
1,666,714
+119,730
+8% +$1.84M 0.04% 234
2024
Q1 		$21.8M Sell
1,546,984
-395,458
-20% -$4.98M 0.03% 252
2023
Q4 		$20.3M Sell
1,942,442
-323,647
-14% -$3.02M 0.04% 238
2023
Q3 		$23.1M Sell
2,266,089
-300,333
-12% -$2.8M 0.05% 216
2023
Q2 		$19.3M Buy
2,566,422
+892,702
+53% +$7.24M 0.04% 248
2023
Q1 		$14.8M Sell
1,673,720
-969,380
-37% -$9.58M 0.03% 289
2022
Q4 		$24.1M Buy
2,643,100
+348,658
+15% +$3.04M 0.06% 219
2022
Q3 		$18.5M Sell
2,294,442
-919,292
-29% -$8.13M 0.06% 232
2022
Q2 		$24.2M Buy
3,213,734
+1,324,951
+70% +$11.5M 0.06% 223
2022
Q1 		$17.7M Sell
1,888,783
-23,543
-1% -$196K 0.04% 271
2021
Q4 		$15.3M Buy
1,912,326
+305,004
+19% +$2.75M 0.04% 294
2021
Q3 		$15.7M Buy
1,607,322
+390,180
+32% +$3.65M 0.04% 284
2021
Q2 		$12.1M Buy
1,217,142
+404,483
+50% +$4.28M 0.03% 318
2021
Q1 		$9.38M Sell
812,659
-251,624
-24% -$2.89M 0.03% 354
2020
Q4 		$10.3M Sell
1,064,283
-133,002
-11% -$1.27M 0.03% 306
2020
Q3 		$10.8M Buy
1,197,285
+316,201
+36% +$3.35M 0.03% 252
2020
Q2 		$10.9M Sell
881,084
-48,010
-5% -$543K 0.04% 244
2020
Q1 		$8.34M Buy
929,094
+41,269
+5% +$423K 0.04% 246
2019
Q4 		$8.7M Buy
887,825
+210,525
+31% +$1.88M 0.03% 281
2019
Q3 		$4.66M Sell
677,300
-210,457
-24% -$1.61M 0.02% 351
2019
Q2 		$8.19M Buy
887,757
+352,843
+66% +$4.25M 0.04% 254
2019
Q1 		$8.39M Sell
534,914
-66,001
-11% -$1.16M 0.04% 239
2018
Q4 		$9.27M Buy
600,915
+44,349
+8% +$909K 0.05% 231
2018
Q3 		$12M Sell
556,566
-30,678
-5% -$712K 0.06% 231
2018
Q2 		$14.3M Sell
587,244
-14,369
-2% -$293K 0.07% 206
2018
Q1 		$10.3M Sell
601,613
-255,485
-30% -$4.99M 0.05% 233
2017
Q4 		$16.2M Buy
857,098
+49,777
+6% +$749K 0.08% 194
2017
Q3 		$14.2M Buy
807,321
+370,380
+85% +$8.33M 0.07% 208
2017
Q2 		$14.5M Sell
436,941
-29,945
-6% -$927K 0.08% 196
2017
Q1 		$15M Buy
466,886
+129,691
+38% +$4.43M 0.07% 193
2016
Q4 		$12.2M Buy
337,195
+123,331
+58% +$4.92M 0.06% 192
2016
Q3 		$9.84M Sell
213,864
-9,928
-4% -$518K 0.05% 214
2016
Q2 		$11.2M Buy
223,792
+19,078
+9% +$1.02M 0.06% 191
2016
Q1 		$11M Sell
204,714
-44,405
-18% -$2.61M 0.07% 165
2015
Q4 		$16.4M Buy
249,119
+8,920
+4% +$551K 0.13% 151
2015
Q3 		$13.6M Sell
240,199
-47,378
-16% -$3.07M 0.1% 161
2015
Q2 		$17M Buy
287,577
+57,685
+25% +$3.56M 0.1% 165
2015
Q1 		$14.3M Sell
229,892
-1,221
-0.5% -$71K 0.08% 183
2014
Q4 		$13.3M Sell
231,113
-41,965
-15% -$2.34M 0.08% 181
2014
Q3 		$14.7M Sell
273,078
-18,485
-6% -$979K 0.08% 174
2014
Q2 		$15.3M Buy
291,563
+3,590
+1% +$183K 0.07% 170
2014
Q1 		$15.2M Buy
287,973
+2,515
+0.9% +$116K 0.08% 161
2013
Q4 		$11.4M Buy
285,458
+5,054
+2% +$199K 0.06% 176
2013
Q3 		$10.6M Buy
280,404
+3,224
+1% +$126K 0.05% 171
2013
Q2 		$10.9M Buy
+277,180
New +$10.8M 0.06% 163

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

VanEck Associates's TEVA Position: Q2 2026 in Review

VanEck Associates reduced its Teva Pharmaceuticals (TEVA) stake by 19% in Q2 2026, selling an estimated $10.3M and leaving 1,356,009 shares worth $45.9M. The position accounts for 0.03% of the portfolio, ranked #299.

VanEck Associates first reported a position in TEVA in Q2 2013 and has held it in 53 quarters since. The position peaked at $50.1M in Q1 2026. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • VanEck Associates held 1,356,009 shares of Teva Pharmaceuticals worth $45.9M as of Q2 2026.
  • VanEck Associates sold 308,449 Teva Pharmaceuticals shares in Q2 2026, an estimated $10.3M.
  • Teva Pharmaceuticals made up 0.03% of VanEck Associates's portfolio in Q2 2026, its #299 holding.
  • VanEck Associates first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • VanEck Associates's Teva Pharmaceuticals position peaked at $50.1M in Q1 2026.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on VanEck Associates's 13F filing for Q2 2026, filed 14 Aug 2026.